Cadence Pharmaceuticals, (FRA:QEW) Days Sales Outstanding : 23.55 (As of Dec. 2013)

View and export this data going back to . Start your Free Trial

What is Cadence Pharmaceuticals, Days Sales Outstanding?

Cadence Pharmaceuticals,'s average Accounts Receivable for the three months ended in Dec. 2013 was €6.65 Mil. Cadence Pharmaceuticals,'s Revenue for the three months ended in Dec. 2013 was €25.78 Mil. Hence, Cadence Pharmaceuticals,'s Days Sales Outstanding for the three months ended in Dec. 2013 was 23.55.

The historical rank and industry rank for Cadence Pharmaceuticals,'s Days Sales Outstanding or its related term are showing as below:

FRA:QEW's Days Sales Outstanding is not ranked ^*
in the Biotechnology industry.
Industry Median: 72.67
* Ranked among companies with meaningful Days Sales Outstanding only.

Cadence Pharmaceuticals,'s Days Sales Outstanding declined from Dec. 2012 (34.87) to Dec. 2013 (23.55).

Cadence Pharmaceuticals, Days Sales Outstanding Historical Data

The historical data trend for Cadence Pharmaceuticals,'s Days Sales Outstanding can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cadence Pharmaceuticals, Days Sales Outstanding Chart

Cadence Pharmaceuticals, Annual Data

Trend

Dec04

Dec05

Dec06

Dec07

Dec08

Dec09

Dec10

Dec11

Dec12

Dec13

Days Sales Outstanding

Get a 7-Day Free Trial

48.27

30.38

25.49

Cadence Pharmaceuticals, Quarterly Data
	Mar09	Jun09	Sep09	Dec09	Mar10	Jun10	Sep10	Dec10	Mar11	Jun11	Sep11	Dec11	Mar12	Jun12	Sep12	Dec12	Mar13	Jun13	Sep13	Dec13
Days Sales Outstanding	Get a 7-Day Free Trial															34.87	28.95	33.35	28.03	23.55

Competitive Comparison of Cadence Pharmaceuticals,'s Days Sales Outstanding

For the Biotechnology subindustry, Cadence Pharmaceuticals,'s Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cadence Pharmaceuticals,'s Days Sales Outstanding Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cadence Pharmaceuticals,'s Days Sales Outstanding distribution charts can be found below:

* The bar in red indicates where Cadence Pharmaceuticals,'s Days Sales Outstanding falls into.

Cadence Pharmaceuticals, Days Sales Outstanding Calculation

Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Accounts Receivable can be measured by Days Sales Outstanding.

Cadence Pharmaceuticals,'s Days Sales Outstanding for the fiscal year that ended in Dec. 2013 is calculated as

	Days Sales Outstanding (A: Dec. 2013 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Dec. 2012 )	+	Accounts Receivable (A: Dec. 2013 ))	/	count )	/	Revenue (A: Dec. 2013 )	*	Days in Period
=	( (4.688	+	6.789)	/	2 )	/	82.166	*	365
=	5.7385					/	82.166	*	365
=	25.49

Cadence Pharmaceuticals,'s Days Sales Outstanding for the quarter that ended in Dec. 2013 is calculated as:

	Days Sales Outstanding (Q: Dec. 2013 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Sep. 2013 )	+	Accounts Receivable (A: Dec. 2013 ))	/	count )	/	Revenue (A: Dec. 2013 )	*	Days in Period
=	( (6.516	+	6.789)	/	2 )	/	25.778	*	365 / 4
=	6.6525					/	25.778	*	365 / 4
=	23.55

Cadence Pharmaceuticals, (FRA:QEW) Days Sales Outstanding Explanation

For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.

Cadence Pharmaceuticals, Days Sales Outstanding Related Terms

Thank you for viewing the detailed overview of Cadence Pharmaceuticals,'s Days Sales Outstanding provided by GuruFocus.com. Please click on the following links to see related term pages.

Cadence Pharmaceuticals, (FRA:QEW) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cadence Pharmaceuticals, Inc. (FRA:QEW) » Definitions » Days Sales Outstanding

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.cadencepharm.com

Cadence Pharmaceuticals, Inc. is a biopharmaceutical company focused on in-licensing, developing and commercializing product candidates mainly for use in the hospital setting. The Company's main activities are conducting research and development activities as well as conducting clinical trials. The company has in-licensed rights to products: Acetavance, an intravenous formulation of acetaminophen, and Omigard, an omiganan pentahydrochloride 1% aqueous gel. It in-licensed the exclusive United States, or U.S., and Canadian rights to Acetavance from Bristol-Myers Squibb Company, or BMS, which markets this product candidate in Europe and other markets for the treatment of acute pain and fever under the brand name Perfalgan. The Company is developing Acetavance, a proprietary intravenous formulation of acetaminophen, for the U.S. market for the treatment of acute pain and fever in adults and children. In its oral form, acetaminophen is the most widely used drug for the treatment of pain and fever in the U.S. The Company's licensor, BMS, currently markets this proprietary intravenous formulation of acetaminophen for the treatment of acute pain and fever in Europe and several other markets outside the U.S, where it is known as paracetamol and is marketed under the brand name Perfalgan.

Cadence Pharmaceuticals, (FRA:QEW) Headlines

No Headlines